29 results
424B5
CHRS
Coherus Biosciences Inc
12 Sep 23
Prospectus supplement for primary offering
6:04am
were outstanding.
Special Stockholder Meetings
The bylaws provide that a special meeting of stockholders may be called by our corporate secretary
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
2 Aug 23
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
4:05pm
with clinical stage anti-IL-27 and anti-CCR8 development programs. The merger is expected to close following the Surface Oncology special meeting
424B3
CHRS
Coherus Biosciences Inc
26 Jul 23
Prospectus supplement
4:59pm
of this proxy statement/prospectus to the date of the Surface special meeting, and through the date the First Merger is consummated. Given that the price per … is traded on the Nasdaq Capital Market (“Nasdaq CM”) under the symbol “SURF.”
Surface will hold a special meeting of its stockholders to consider and vote
S-4/A
EX-99.2
bpi2jya 8ncbk
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
S-4/A
7amrmspwjcyzlx5u
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
S-4
us9n4rt0m3nurmii 3u
7 Jul 23
Registration of securities issued in business combination transactions
5:03pm
425
jmb5y
16 Jun 23
Business combination disclosure
8:08am
425
rm8z0ezojij9qkday88x
16 Jun 23
Business combination disclosure
7:09am
8-K
EX-2.1
t3zdneu1tfoqyi
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
424B5
n0l4egw0mbsu
17 May 23
Prospectus supplement for primary offering
4:02pm
424B5
wky lqmqfqjn
16 May 23
Prospectus supplement for primary offering
6:07am
424B5
2ni63
17 Nov 22
Prospectus supplement for primary offering
5:37pm
8-K
EX-3.1
w2592va33oouz7sks
18 Nov 20
Departure of Directors or Certain Officers
4:06pm
424B5
ri3k5guszrm9c3
23 May 18
Prospectus supplement for primary offering
5:27pm
424B5
387cqfsuqjcpdao6
21 May 18
Prospectus supplement for primary offering
5:20pm